How Often Should You Receive MRD Testing While In Remission?
How Often Should You Receive MRD Testing While In Remission? image
Apr 12, 2022 / 01:00PM - 02:00PM EDT
Minimal Residual Disease (MRD) Chapter

Event Description

While remission (or state of complete response) can be an exciting time for myeloma patients, there might be a level of stress surrounding the monitoring of the disease for the inevitable relapse. And while MRD testing can help provide insight on the disease's activity within the body, excessive MRD testing might become costly or negatively affect your quality of life. Here to help share insight on this complicated topic is multiple myeloma specialist Dr. Joshua Richter from Mount Sinai Hospital in NYC. Be prepared to learn with us and come with questions!

Schedule & Agenda

person
Introduction
01:00PM
Audrey Burton-Bethke
Audrey introduces the agenda of the event and featured speaker Dr. Joshua Richter.
person
Presentation
01:05PM
Joshua Richter, MD.
Dr. Joshua Richter shares his insight on how often MRD testing should be done.
person
Questions and Answers
01:35PM
Audience
Type your questions in the chat and we will answer them!

Speakers & Moderators

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
The panelist Joshua Richter, MD
Joshua Richter, MD

Joshua Richter, MD, is Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology. He is the director of Multiple Myeloma at the Blavatnik Family- Chelsea Medical Center at Mount Sinai. Dr. Richter treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, plasma cell leukemia, and Waldenstrom’s Macroglobulinemia. Dr. Richter has extensive experience with clinical trials focused on novel therapies, including antibody therapy and immunotherapy for a precision medicine approach. He has published extensively on these topics and has been invited to speak regionally, nationally, and also internationally. He has been published in journals such as the New England Journal of Medicine, Blood, and the Journal of Clinical Oncology.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

+1 800 709 1113

email

Support@healthtree.org

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Legend Biotechnologies
Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811